A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Dexanabinol (Primary)
- Indications Anaplastic astrocytoma; Brain cancer; Brain metastases; Glioblastoma; Glioma; Meningioma
- Focus Adverse reactions
- 09 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016.
- 22 Mar 2016 Status changed from active, no longer recruiting to completed, according to e-Therapeutics media release.
- 23 Nov 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.